Title:
ARYLOXY COMPOUND
Document Type and Number:
WIPO Patent Application WO/2019/131922
Kind Code:
A1
Abstract:
The present invention provides a compound that has β2-adrenergic receptor antagonist activity and carbonic anhydrase-inhibitory activity, and that exhibits excellent ocular antihypertensive activity. Specifically provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A represents an optionally substituted phenyl group, etc. R1 and R2 each independently represent a hydrogen atom, etc. X1 represents a single bond, etc. X2 represents a single bond, etc. B denotes formula (AA) or formula (BB) (where W1 represents a nitrogen atom, etc.; W2 represents an oxygen atom, etc.; W3 represents a nitrogen atom, etc.; Rb1 represents an optionally substituted phenyl group, etc.; and Rb2 represents a hydrogen atom, etc.)]
Inventors:
NAGAI KEITA (JP)
TAMURA RIE (JP)
OGIWARA TATSUYA (JP)
OHARA JUNICHIRO (JP)
YASUKAWA KEN (JP)
IZUTA AYAKO (JP)
FUJIKAWA TORU (JP)
TAMURA RIE (JP)
OGIWARA TATSUYA (JP)
OHARA JUNICHIRO (JP)
YASUKAWA KEN (JP)
IZUTA AYAKO (JP)
FUJIKAWA TORU (JP)
Application Number:
PCT/JP2018/048284
Publication Date:
July 04, 2019
Filing Date:
December 27, 2018
Export Citation:
Assignee:
SATO PHARMA (JP)
International Classes:
C07C311/37; A61K31/18; A61K31/277; A61K31/381; A61K31/415; A61K31/4155; A61K31/433; A61K31/454; A61K31/5377; A61P27/02; A61P27/06; A61P43/00; C07D231/12; C07D285/10; C07D333/34; C07D409/04; C07D417/12
Domestic Patent References:
| WO2002006229A2 | 2002-01-24 | |||
| WO2002048134A2 | 2002-06-20 | |||
| WO2002006274A1 | 2002-01-24 | |||
| WO2012086727A1 | 2012-06-28 |
Other References:
DATABASE CAS [online] US : American Chemical Society; 2011, retrieved from STN Database accession no. 1348362-21-9
Attorney, Agent or Firm:
TANAKA Shinichiro et al. (JP)
Download PDF: